Overview:
Advancements in understanding the molecular drivers of adult and pediatric gliomas, including alterations in IDH, H3, BRAF, and other actionable targets, have paved the way for a rapid expansion of personalized treatment options across the glioma spectrum. However, translating comprehensive molecular profiling into timely, evidence-based treatment decisions remains challenging because of heterogeneity in testing practices, evolving therapeutic targets, and limited familiarity with recently approved agents and emerging clinical trial data.
This live/virtual hybrid Tumor Board–style symposium will bring
together experts in the management of adult and pediatric gliomas to discuss
novel targeted and molecularly guided therapies through real-world case
reviews. Faculty will provide an overview of key molecular profiles and
biomarkers in low-grade and high-grade gliomas, address persistent unmet needs
in the care of both adult and pediatric patients, and highlight innovative,
tailored approaches that are reshaping the future of glioma management. Case-based
discussions will help clinicians interpret molecular testing results, compare
emerging targeted options for distinct glioma subtypes, and develop practical
strategies to integrate recently approved and investigational therapies into
clinical practice to optimize outcomes for patients with these tumors.
Learning Objectives:
Upon completion of this activity, participants will be able to:
- Integrate current classification criteria and diagnostic strategies for identifying adult and pediatric patients with glioma
- Incorporate genetic and molecular information to classify gliomas and develop personalized treatment plans accurately
- Evaluate the data for recent advancements in targeted agents, immunotherapies, and other innovative treatment methods for treating patients with gliomas
- Identify strategies to integrate targeted therapies, immunotherapies, and novel emerging treatment approaches for managing pediatric patients with gliomas.
Target Audience:
This educational activity is directed toward physicians,
nurses, NP/PAs, and other HCPs involved in the treatment and management of
gliomas.
Vinay K. Puduvalli, MD
Professor and Chair, Department of Neuro-Oncology
Co-Director, Cancer Neuroscience Program
Co-Director, NeuroHealth Initiative
The University of Texas MD Anderson Cancer Center
Houston, TX
Manmeet Ahluwalia, MD, MBA
Professor of Translational Medicine
Herbert Wertheim College of Medicine, Florida International University
Fernandez Family Foundation Endowed Chair in Cancer Research
Chief of Medical Oncology
Chief Scientific Officer & Deputy Director
Miami Cancer Institute, Baptist Health South Florida
Miami, FL
Ashley S. Margol, MD, MS
Director, Brain Tumor Center and Neuro-Oncology Program
Cancer and Blood Disease Institute at Children’s Hospital Los Angeles
Project Co-Leader, Pediatric Neuro-Oncology Consortium
Associate Professor of Clinical Pediatrics
Keck School of Medicine of University of Southern California
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.
